Core Viewpoint - The company, Seer Medical Technology Group Co., Ltd., has decided not to exercise the early redemption rights for its convertible bonds, despite meeting the conditions for redemption due to stock price performance [1][6]. Group 1: Convertible Bond Redemption - The company's stock price has met the condition of being above 130% of the conversion price for at least 15 trading days within a 30-day period, triggering the redemption clause for the "Seer Convertible Bonds" [1][6]. - The board of directors has resolved not to redeem the "Seer Convertible Bonds" early, considering current market conditions and the protection of investor interests [1][7]. - The company will not exercise the early redemption rights for the next three months, and if the redemption conditions are met again after October 21, 2025, the board will reconvene to decide on the matter [1][6]. Group 2: Convertible Bond Issuance and Terms - The company issued 5.4331 million convertible bonds at a face value of 100 yuan each, totaling 534.698 million yuan, with the net proceeds after expenses amounting to 532.698 million yuan [1][2]. - The initial conversion price was set at 16.98 yuan per share, with the conversion period running from March 1, 2021, to August 20, 2026 [2][3]. - The conversion price has been adjusted multiple times, with the latest adjustment reducing it from 12.50 yuan to 12.00 yuan per share, effective from February 6, 2025 [5][6]. Group 3: Compliance and Oversight - The company has adhered to necessary decision-making procedures regarding the non-redemption of the convertible bonds, in compliance with relevant regulations and guidelines [7][8]. - The sponsor institution has confirmed that the decision not to redeem the bonds early is in line with legal requirements and the company's offering documents [7][8].

信达证券股份有限公司 关于塞力斯医疗科技集团股份有限公司 不提前赎回"塞力转债"的核查意见 信达证券股份有限公司（以下简称"信达证券""保荐机构"）作为塞力斯医 疗科技集团股份有限公司（以下简称"塞力医疗""公司"）公开发行可转换公司 债券的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所股 票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》及 《上海证券交易所上市公司自律监管指引第 12 号——可转换公司债券》等相关 规定，经审慎核查，就塞力医疗不行使"塞力转债"的提前赎回权利，发表如下 核查意见： 一、可转换公司债券发行上市概况 （一）可转换公司债券发行情况 二次下修转债转股价格：经 2024 年第五次临时股东大会审议通过并授权董 事会根据《募集说明书》中相关条款办理本次向下修正转股价格相关事宜，包括 确定本次修正后的转股价格、生效日期以及其他必要事项，并全权办理相关手续。 公司同日于 2024 年 10 月 24 日召开第五届董事会第七次会议，审议通过了《关 于确定向下修正"塞力转债"转股价格的议案》，同意将"塞力转债"转股价格由 13.71 元/股向下修正为 12. ...

| 证券简称：塞力医疗 | 公告编号：2025-066 | | --- | --- | | 债券简称：塞力转债 | | | 证券代码：603716 债券代码：113601 | | 塞力斯医疗科技集团股份有限公司 关于不提前赎回"塞力转债"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 塞力斯医疗科技集团股份有限公司（以下简称"公司"或"塞力医疗"） 股票自2025年7月1日至7月21日期间，已满足连续三十个交易日中至少有十五个 交易日的收盘价不低于当期转股价格的130%（即15.60元/股），已触发"塞力转 债"的赎回条款。公司董事会决定本次不行使"塞力转债"的提前赎回权利，不 提前赎回"塞力转债"。 未来三个月内（即2025年7月22日至2025年10月21日），如公司触发"塞 力转债"的赎回条款均不行使"塞力转债"的提前赎回权利。以2025年10月21 日之后的首个交易日重新起算，若"塞力转债"再次触发赎回条款，届时公司董 事会将再次召开会议决定是否行使"塞力转债"的提前赎回权利。 一、可转换公司债 ...

医药商业板块震荡走高，人民同泰（600829）拉升涨停，华人健康（301408）、塞力医疗（603716）、 漱玉平民（301017）、药易购（300937）跟涨。 ...

Trading Information Summary - On July 18, 2025, Saily Medical (603716) closed at 23.7 yuan, down 0.59%, with a turnover rate of 30.59% and a trading volume of 584,400 shares, amounting to a total transaction value of 1.379 billion yuan [1] - On the same day, the net outflow of main funds was 21.5478 million yuan, accounting for 1.56% of the total transaction value, while the net inflow of retail funds was 26.3924 million yuan, accounting for 1.91% [1][4] - Saily Medical appeared on the "Dragon and Tiger List" for the fourth time in the last five trading days due to a daily turnover rate reaching 20% [1][4] Company Announcement Summary - Saily Medical announced that its controlling shareholder, Saihai Technology, has released the pledge on 1,100,000 shares, which is part of the 21,642,540 shares it holds, representing 11.33% of the total share capital [2] - After the release of the pledge, Saihai Technology has a total of 14,000,000 pledged shares, accounting for 64.69% of its holdings and 7.33% of the total share capital [2] - The actual controller, Wen Wei, holds 9,634,208 shares, representing 5.04% of the total share capital, with 8,300,000 shares pledged, accounting for 86.15% of his holdings [2] - The total number of pledged shares by Saihai Technology and Wen Wei is 22,300,000, which accounts for 71.30% of their combined holdings and 11.67% of the total share capital [2][4] - The company states that the pledge risk is under control and will not affect its operations, main business, financing credit, or ability to continue operations [2]

Market Performance - A-shares steadily advanced this week, with the ChiNext Index reaching a new high for the year and the Shenzhen Component Index hitting a four-month high, approaching its highest point of the year [1] - Weekly trading volume increased to 7.73 trillion yuan, marking the largest weekly trading volume in three months [1] Fund Inflows - Leverage funds actively entered the market, with most industries under the Shenwan first-level industry classification seeing net buying, particularly the computer industry with over 4.4 billion yuan and the electronics industry with over 3 billion yuan [2] - The electronic, biopharmaceutical, and automotive sectors each received over 20 billion yuan in net inflows, while the non-bank financial sector saw a net outflow of over 8.3 billion yuan [2] Rare Earth Demand - The rare earth sector performed strongly, with the rare earth permanent magnet index reaching a three-and-a-half-year high [3] - Demand for rare earths is expected to grow rapidly due to advancements in humanoid robots and electric vehicles, with estimates suggesting a demand of at least 70,000 tons of neodymium-iron-boron by 2025 [3] Energy Metals - The energy metals sector, including lithium and cobalt, reached a two-year high, with lithium carbonate futures breaking 70,000 yuan/ton, marking a 20% increase from recent lows [4] - Short-term lithium salt supply may decline due to reduced exports from Chile and domestic production halts, leading to a potential price stabilization [4] Biopharmaceutical Sector - The biopharmaceutical sector saw significant gains, with the innovative drug index hitting record highs multiple times this week [6] - Notable stocks in the sector, such as Lianhuan Pharmaceutical and Aosaikang, experienced consecutive trading halts, with some stocks showing year-to-date gains exceeding 200% [6][7] Earnings Forecasts - Several pharmaceutical companies have recently forecasted substantial profit increases for the first half of 2025, with estimates suggesting net profit growth exceeding 19 times for some firms [7]

Core Insights - Celer Medical has seen a significant increase in trading activity, with a turnover rate exceeding 20% on July 18, leading to its appearance on the stock market's "龙虎榜" [1] - The stock has been actively traded, appearing on the list 14 times in the past month, indicating high market liquidity [2] Buying Activity - The top buyer was Guotai Junan Securities Headquarters, purchasing shares worth 49.083 million yuan, followed by CITIC Securities Shanghai Branch and JPMorgan Securities Shanghai Yincheng Road Branch among the top five buyers [1] - An institutional special seat participated with a purchase of 29.436 million yuan, with a historical 3-day post-purchase increase probability of 43.02% for stocks that appeared on the list [1] Selling Activity - The leading seller was also Guotai Junan Securities Headquarters, selling shares worth 38.4318 million yuan, followed closely by CITIC Securities Shanghai Branch and Hualin Securities Beijing Branch [1] - JPMorgan Securities Shanghai Yincheng Road Branch and CITIC Securities Shanghai Branch were also active in selling, with sales of 26.666 million yuan and 26.6436 million yuan respectively [1] Trading Characteristics - Some brokerage firms exhibited dual trading characteristics, appearing on both the buying and selling sides, including Guotai Junan Securities Headquarters and CITIC Securities Shanghai Branch [1] - JPMorgan Securities Shanghai Yincheng Road Branch had the highest probability of a 3-day post-trade increase at 47.19% among both buyers and sellers [1] Market Perception - CITIC Securities Shanghai Branch and CITIC Securities Shanghai Branch are viewed as important trading channels for active funds in the market [1] - The trading activity of JPMorgan Securities Shanghai Yincheng Road Branch is closely monitored due to its frequent participation in popular stock trades [1]

Core Viewpoint - The announcement details the partial release of share pledges by the controlling shareholder of Saily Medical Technology Group Co., Ltd., indicating a significant portion of shares remains pledged while highlighting the financial stability and repayment capability of the shareholders [2][4][5]. Group 1: Share Pledge Release - The controlling shareholder, Saihai (Shanghai) Health Technology Co., Ltd., has released 1,100,000 shares from pledge, reducing the total pledged shares to 14,000,000, which is 64.69% of their holdings and 7.33% of the total shares [2][3]. - The actual controller, Mr. Wen Wei, holds 9,634,208 shares, with 8,300,000 shares pledged, representing 86.15% of his holdings and 4.35% of the total shares [2][4]. Group 2: Pledge Situation - The total pledged shares by Saihai Technology and Mr. Wen Wei amount to 22,300,000, which is 71.30% of their combined holdings and 11.67% of the total shares [2][4]. - Within the next six months, 6,000,000 shares are due for pledge expiration, which is 19.18% of their holdings and 3.14% of the total shares, with a corresponding financing balance of 14.61 million [4]. - The funds from the pledges are primarily used to repay previous financing debts, with repayment sources including personal funds and investment returns, indicating a manageable risk level [4][5]. Group 3: Future Considerations - Following the release of shares from pledge, Saihai Technology will decide on future pledges based on business needs and financial arrangements [6]. - The company will continue to monitor the pledge and release situations of the controlling shareholder and comply with disclosure obligations [6].

Group 1 - The innovative drug concept index rose by 2.68%, ranking 9th among concept sectors, with 197 stocks increasing in value [1] - Notable gainers included Chengdu Xian Dao, Weikang Pharmaceutical, and Maiwei Biotech, each reaching a 20% limit up, while Seli Medical, Lisheng Pharmaceutical, and Xinlitai also hit the limit up [1] - The top gainers in percentage terms were Meidi Xi, Shouyao Holdings, and Shenzhou Cell, with increases of 19.00%, 15.54%, and 15.40% respectively [1] Group 2 - The innovative drug sector saw a net inflow of 1.07 billion yuan, with 104 stocks receiving net inflows, and 8 stocks exceeding 100 million yuan in net inflow [2] - Seli Medical led the net inflow with 222 million yuan, followed by Shenzhou Cell, WuXi AppTec, and Xinlitai with net inflows of 217 million yuan, 203 million yuan, and 147 million yuan respectively [2] - The top stocks by net inflow ratio included Han Shang Group, Weikang Pharmaceutical, and Seli Medical, with net inflow ratios of 56.11%, 17.61%, and 17.43% respectively [3] Group 3 - The innovative drug sector's performance was contrasted by the decline of ST Unimed, *ST Suwu, and Guangsheng Tang, which fell by 5.01%, 4.81%, and 4.41% respectively [1][2] - The overall market sentiment reflected a mixed performance across various sectors, with some sectors like military restructuring and AI-related concepts showing positive trends while others like housing inspection and cement concepts experienced slight declines [2]

Core Viewpoint - The brain engineering sector experienced a rise of 1.48% on July 17, with a total capital outflow of 385.08 million [1] Group 1: Stock Performance - A total of 27 stocks in the sector increased in value, while 5 stocks declined [1] - The top-performing stocks included: - Seli Medical: +10.01% - Boji Pharmaceutical: +9.5% - Innovation Medical: +3.23% - Pulite: +3.03% - Beilu Pharmaceutical: +2.6% [1] Group 2: Capital Flow - Major stocks with significant capital inflow included: - Innovation Medical: +16.07 million, accounting for 2.21% - Seli Medical: +199 million, accounting for 15.64% [1] - Stocks with capital outflow included: - Boji Pharmaceutical: -2.46 million, accounting for -2.82% - Beilu Pharmaceutical: -1.41 million, accounting for -3.62% [1] Group 3: Declining Stocks - The stocks that saw the largest declines included: - ST Huatuo: -4.77% - Botuo Bio: -1.59% - Hanwei Technology: -1.49% [1]